The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales

U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales

January 15, 2017 • By Andrew Chung

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them.

You Might Also Like
  • U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight
  • U.S. Supreme Court Speeds Copycat Biologic Drugs to Market
  • U.S. Top Court Debates Making Copycat Biologics Available Sooner

The justices will take up an appeal by Novartis AG of a 2015 federal appeals court decision that prevented the Swiss pharmaceutical company from selling its biosimilar version of California-based Amgen Inc.’s $1-billion-a-year Neupogen until six months after the U.S. Food and Drug Administration approved it. The case could determine how quickly patients have access to biosimilar medicines at potentially cheaper prices.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Unlike traditional drugs, biologic drugs cannot be copied exactly to make generic versions. A 2010 federal law allows companies to seek approval to sell near-copies, called biosimilars.

Biologic drugs are complex chemicals made inside living cells. Insurers expect biosimilars, like generics, to be cheaper than original brands.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Novartis unit Sandoz in September 2015 began selling Zarxio, the first biosimilar to win regulatory approval in the U.S. Neupogen and Zarxio boost white blood cell counts in cancer patients to help fight infections.

Zarxio, which costs 15% less than Neupogen at list prices, has since exceeded $100 million in sales, according to Novartis.

The dispute arose when Amgen sued Sandoz in 2014 in San Francisco federal court alleging patent infringement and violations of the law governing biosimilars. The companies disagreed on how to apply the law’s requirement that a biosimilar drug maker give the brand-name manufacturer 180 days notice before launching its copycat version.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In July 2015, the U.S. Court of Appeals for the Federal Circuit in Washington ruled that the 180-day notice must be given after FDA approval.

Novartis last February appealed that decision to the Supreme Court, saying the Federal Circuit’s ruling improperly gave the brand-name manufacturer an extra six months of exclusivity on top of the 12 years already provided for under the law, driving up health care costs.

“If not reversed, (it) will delay access by patients to all biosimilars for six months longer than Congress intended,” Novartis said in its petition asking the Supreme Court to take up the case.

In opposing Novartis’ appeal, Amgen told the Supreme Court that the statute was meant to foster innovation and clearly states that the 180-day period cannot begin until the biosimilar is approved.

The Supreme Court in December declined to hear a similar case involving Canadian generic drug maker Apotex Inc. and Amgen.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Legal Tagged With: Biologics, Biologics & Biosimilars, Biosimilars, lawsuit, Legal, Supreme Court

You Might Also Like:
  • U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight
  • U.S. Supreme Court Speeds Copycat Biologic Drugs to Market
  • U.S. Top Court Debates Making Copycat Biologics Available Sooner
  • Novartis Bid to Sell New Biosimilar Crimped by U.S. Court Battles

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)